EPISODE · Jan 28, 2026 · 2 MIN
ACT Brief: ESG Moves Into Vendor Oversight, RWE Faces Governance Hurdles, and Roche Advances Obesity Pipeline
from Applied Clinical Trials · host Applied Clinical Trials
In today’s ACT Brief, we examine why ESG efforts in clinical development are shifting into vendor oversight, what data and governance barriers still limit broader use of de-identified RWE in submissions, and new Phase II obesity data from Roche as its program moves toward Phase III.
Embed this episode
Ready to play
ACT Brief: ESG Moves Into Vendor Oversight, RWE Faces Governance Hurdles, and Roche Advances Obesity Pipeline
0:00
2:05
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Applied Clinical Trials?
This episode is 2 minutes long.
When was this Applied Clinical Trials episode published?
This episode was published on January 28, 2026.
Can I download this Applied Clinical Trials episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!